Pharmacological Modulation of the Psychiatric Risk Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs
Despite a growing body of research over the last few decades, mental disorders, including anxiety disorders or depression, are still one of the most prevalent and hardest to treat health burdens worldwide. Since pharmacological treatment with a single drug is often rather ineffective, approaches suc...
Main Authors: | Max L. Pöhlmann, Alexander S. Häusl, Daniela Harbich, Georgia Balsevich, Clara Engelhardt, Xixi Feng, Michaela Breitsamer, Felix Hausch, Gerhard Winter, Mathias V. Schmidt |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Behavioral Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnbeh.2018.00262/full |
Similar Items
-
FKBP Ligands—Where We Are and Where to Go?
by: Jürgen M. Kolos, et al.
Published: (2018-12-01) -
The Many Faces of FKBP51
by: Andreas Hähle, et al.
Published: (2019-01-01) -
Is Autophagy Involved in the Diverse Effects of Antidepressants?
by: Theo Rein
Published: (2019-01-01) -
FKBP51 increases the tumour‐promoter potential of TGF‐beta
by: Simona Romano, et al.
Published: (2014-12-01) -
Sex differences in the effect of the FKBP5 inhibitor SAFit2 on anxiety and stress-induced reinstatement following cocaine self-administration
by: Krista L. Connelly, et al.
Published: (2020-11-01)